New daily pill shows promise for obesity and diabetes in early trial
NCT ID NCT05184322
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase study tested an oral tablet called ecnoglutide in 87 healthy adults. The drug is a GLP-1 analogue, similar to existing injectable treatments for type 2 diabetes and obesity, but designed to be taken by mouth. The main goal was to check safety and how the body processes the drug, not yet to measure weight loss or blood sugar control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ecnoglutide (a GLP-1 analogue)
- What this could lead to
- If successful, this could lead to a convenient daily pill for managing obesity and type 2 diabetes.
- What could go wrong
- This is a very early Phase 1 trial in healthy people, so safety and effectiveness are not yet known. Many early drugs fail to show benefit in later trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Q-Pharm Pty Ltd (AKA Nucleus Network Brisbane)
Herston, Queensland, 4006, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new stomach and gut bypass surgery tackle obesity and diabetes?
- Can a Two-Drug combo tip the scales against obesity?
- Can Weight-Loss surgery change how medications work?
- Could a blood flow 'Tourniquet' workout repair diabetic nerve damage?
- Could a common diabetes drug weaken your bones?
- Coffee grounds probiotic could reshape gut health and fight inflammation